We identified high levels of BIM mRNA expression as a predictive marker of response, progression-free survival (PFS) and overall survival (OS) in erlotinib-treated EGFR-mutant NSCLC patients8. Here, BCL2L11 is linked to non-small cell lung carcinoma.